Home / Health / New Drug Promises Unprecedented Weight Loss
New Drug Promises Unprecedented Weight Loss
12 Dec
Summary
- Retatrutide trial shows nearly 29% body weight loss in 15 months.
- Drug targets three appetite and metabolism hormones.
- Participants reported significant reduction in knee pain.
A promising new weight loss drug, retatrutide, developed by Eli Lilly, has demonstrated significant efficacy in a recent clinical trial. In a 15-month study, participants taking the highest dose achieved an average body weight loss of 29%, equating to 71 pounds. This marks a substantial advancement compared to currently available treatments.
The experimental medication targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon, a triple-action approach not seen in other weight loss drugs. Beyond weight reduction, participants reported a 60% greater decrease in knee pain compared to the placebo group, indicating potential benefits for obesity-related joint issues.
While the full study results are pending peer review, these initial findings suggest retatrutide could offer a powerful new option for individuals struggling with obesity. Eli Lilly plans to seek FDA approval after completing additional studies, with pricing to be determined post-approval.
